Free Trial
OTCMKTS:IPSEY

Ipsen (IPSEY) Stock Price, News & Analysis

Ipsen logo
$28.39 +0.57 (+2.05%)
(As of 11/21/2024 ET)

About Ipsen Stock (OTCMKTS:IPSEY)

Key Stats

Today's Range
$28.39
$28.39
50-Day Range
$27.82
$31.77
52-Week Range
$26.97
$34.06
Volume
833 shs
Average Volume
1,448 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
0.74%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Receive IPSEY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ipsen and its competitors with MarketBeat's FREE daily newsletter.

IPSEY Stock News Headlines

What This Post-Election Shift Means for Your Investments
The election may be over, but its impact on financial markets is only beginning. New trends are emerging, bringing both challenges and opportunities for investors. Many of these changes are flying under the radar, yet they have the potential to reshape the financial landscape for years to come. Understanding how these shifts could affect your wealth—and what steps to take—has never been more important.
Ipsen Q3 Sales Increase; Lifts FY24 Outlook - Quick Facts
See More Headlines

IPSEY Stock Analysis - Frequently Asked Questions

Ipsen's stock was trading at $29.48 at the beginning of the year. Since then, IPSEY stock has decreased by 3.7% and is now trading at $28.3850.
View the best growth stocks for 2024 here
.

Shares of IPSEY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
N/A
Current Symbol
OTCMKTS:IPSEY
CIK
N/A
Employees
5,300
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.58 billion
Cash Flow
$3.52 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.95

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (OTCMKTS:IPSEY) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners